Medivir Ab

Janssen Sciences Ireland Uc

Janssen R&d Ireland

Tibotec Pharmaceuticals Ltd.

Per-Ola Mikael Johansson

Pierre Jean-Marie Bernard Raboisson

Abdellah Tahri

Sandrine Marie Helene Vendeville

Lili Hu

Herman Augustinus De Kock

Dominique Louis Nestor Ghislain Surleraux

Kenneth Simmen

Bengt Bertil Samuelsson

Karl Magnus Nilsson

Vladimir Kirillovich Ivanov

Mikael Pelcman

Åsa Annica Kristina Rosenquist

Bertil Samuelsson

Ingemar Sven-Anders Kvarnstrom

Anna Karin Gertrud Linea Belfrage

Fredrik Thorstensson

Asa Rosenquist

Hans Kristian Wallberg

Anna Karin Gertrud Linnea Belfrage

Bjorn Olof Classon

Susana Ayesa

Vladimir Ivanov

Michael Pelcman

Anna Karin Belfrage

Laszlo Rakos

Kenneth Alan Simmen

Hans Wallberg

ÅSa Annica Kristina Rosenquist

Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. 

HCV NS-3 serine protease inhibitors

Inhibitors of HCV replication of formula (I) 

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond;

Macrocylic inhibitors of hepatitis C virus

Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. 

Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

Growing community of inventors

Huddinge, Sweden

Per-Ola Mikael Johansson